Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation

Clinical Nephrology

Volumn 45, Issue 5, 1996, Pages 332-335

  Wagner, K ^a   Herget, S ^b   Heemann, U ^b  

^a ASKLEPIOS HOSPITAL BARMBEK   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Acute rejection; Kidney transplantation; Rescue therapy; Tacrolimus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; STEROID; TACROLIMUS;

ARTICLE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; META ANALYSIS;

ANIMALS; GRAFT REJECTION; HEMODYNAMIC PROCESSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; TACROLIMUS;

EID: 0029892296     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Becker G, Baltes A, Philipp Th, Wagner K 1993 Comparison of the influence of cyclosporin and FK506 on postischemic renal failure in rats. JASN 4: A909
2. Chen H, Becker K, Wagner K, Philipp Th, Fritschka E 1993 FK506 vermindert die endothelabhängige Relaxation von RattenMesenterialarterien weniger als Cyclosporin. 17. Tagung der wissenschaftlichen Sektion der Deutschen Liga zur Bekämpfung des hohen Blutdrucks, Abstractband: S 49
3. European FK506 Multicentre Liver Study Group 1994 Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344: 423-428
4. European FK506 Kidney Study Group 1993 European pilot multicentre randomized study to compare the efficacy and safety of FK506 and cyclosporin in patients undergoing primary renal transplantation JASN 4: A966
5. Felser I, Wagner S, Depee J 1991 Changes of quality of life following conversion from CyA to FK506 in orthotopic liver transplantation. Transplant Proc 23: 3032-3034
6. Frei U, Wagner K 1994 Renal function in liver transplant patients receiving FK506 or Cyclosporin A immunosuppressive therapy. Transplant Proc 26: 3270-3271
7. Fung J, Abu-Elmagd K, Jain A 1991 A randomized trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine. Transplant Proc 23: 2977-2983
8. Herget S, Schmitt V, Philipp Th, Wagner K 1993 Compairson of vasoconstriction by FK506 and Cyclosporin measured by duplex-Doppler sonography JASN 4: A940
9. Japanese FK506 Study Group 1994 Two-year follow-up study of the efficacy and safety of FK506 in kidney transplant patients. Transplant Int 7 (Suppl 1): 247-251
10. Laskow D, Vincenti F, Neylan J 1995 One year follow-up of the FK506 phase II clinical trial in renal transplantation. Transplant Proc 27: 125
11. Lieberman K, Lin W, Reisman L 1991 FK506 is a direct glomeruloconstrictor as determined by electrical resistance pulse sizing (ERPS). Transplant Proc 23: 3119-3120
12. McCauley J, Farkus Z, Prasad S 1991 Cyclosporine and FK506 induced inhibition of renal epithelial cell proliferation. Transplant Proc 23: 2829-2831
13. Moutabarrik A, Ishibashi M, Fukunaga M 1991 FK506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular toxicity in vitro. Transplant Proc 23: 3133-3137
14. Shapiro R, Jordan M, Scantlebury V 1991 FK506 in clinical kidney transplantation. Transplant Proc 23: 3065-3067
15. The U.S. Multicenter FK506 Liver Study Group 1994 A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331: 1110-1115
16. Ueda D, Tajima A, Ohtawara Y 1991 Influence of FK506 on renal blood flow. Transplant Proc 23: 3121-3123
17. Wagner K, Metz-Kurschel U, Claus M, Philipp Th 1991 Effect of FK506 on the excretion of urinary enzymes in rats. Transplant Proc 23: 3123-3126